[go: up one dir, main page]

FR2842210B1 - Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique - Google Patents

Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique

Info

Publication number
FR2842210B1
FR2842210B1 FR0208636A FR0208636A FR2842210B1 FR 2842210 B1 FR2842210 B1 FR 2842210B1 FR 0208636 A FR0208636 A FR 0208636A FR 0208636 A FR0208636 A FR 0208636A FR 2842210 B1 FR2842210 B1 FR 2842210B1
Authority
FR
France
Prior art keywords
targets
preparing
serum
bacterial infections
pathogenic microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0208636A
Other languages
English (en)
Other versions
FR2842210A1 (fr
Inventor
Sonia Escaich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mutabilis SA
Original Assignee
Mutabilis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0208636A priority Critical patent/FR2842210B1/fr
Application filed by Mutabilis SA filed Critical Mutabilis SA
Priority to DE60320797T priority patent/DE60320797D1/de
Priority to CA002491847A priority patent/CA2491847A1/fr
Priority to ES03762684T priority patent/ES2306891T3/es
Priority to AT03762684T priority patent/ATE394503T1/de
Priority to AU2003266246A priority patent/AU2003266246A1/en
Priority to PCT/EP2003/008209 priority patent/WO2004005535A2/fr
Priority to EP03762684A priority patent/EP1523572B1/fr
Priority to DK03762684T priority patent/DK1523572T3/da
Priority to JP2004518773A priority patent/JP2006515155A/ja
Priority to US10/520,820 priority patent/US20060003393A1/en
Publication of FR2842210A1 publication Critical patent/FR2842210A1/fr
Priority to HK05109367A priority patent/HK1078902A1/xx
Priority to US11/506,821 priority patent/US20070111229A1/en
Priority to AU2009201727A priority patent/AU2009201727A1/en
Priority to US12/729,630 priority patent/US20110236886A1/en
Application granted granted Critical
Publication of FR2842210B1 publication Critical patent/FR2842210B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode pour identifier un gène requis pour la prolifération in vivo d'un microorganisme pathogène, comprenant- l'utilisation d'une souche du microorganismes pathogène,- la génération de mutants d'inactivation dans les gènes codant pour ces facteurs,- la détermination de la virulence de ces mutants sur modèle expérimental d'infection, et de leur effet sur la colonisation entérique chez un modèle de souris axénique, et- la sélection des gènes bactériens essentiels pour la résistance au sérum in vitro, et essentiels chez l'hôte pour la dissémination sérique.Application au criblage de composés inhibiteurs des produits des gènes identifiés et à l'inhibition in vitro de la prolifération d'un mircroorganisme pathogène dans le sérum.
FR0208636A 2002-07-09 2002-07-09 Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique Expired - Lifetime FR2842210B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0208636A FR2842210B1 (fr) 2002-07-09 2002-07-09 Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US10/520,820 US20060003393A1 (en) 2002-07-09 2003-07-09 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
ES03762684T ES2306891T3 (es) 2002-07-09 2003-07-09 Determinantes de patogenicidad que se pueden usar como dianas para desarrrollar medios para la prevencion y el control de infecciones bacterianas y/o diseminacion sistemica.
AT03762684T ATE394503T1 (de) 2002-07-09 2003-07-09 Pathogene determinanten als zielmoleküle zur entwicklung von mitteln welche bakterielle infektionen und/oder systemische verbreitung verhindern und kontrollieren können
AU2003266246A AU2003266246A1 (en) 2002-07-09 2003-07-09 Pathogenicity proteins which can be used as targets for developing means for preventing and controlling bacterial infections
PCT/EP2003/008209 WO2004005535A2 (fr) 2002-07-09 2003-07-09 Determinants a pathogenicite pouvant etre utilises comme cibles en vue du developpement de moyens de prevention et de controle d'infections bacteriennes et/ou de dissemination systemique
EP03762684A EP1523572B1 (fr) 2002-07-09 2003-07-09 Determinants a pathogenicite pouvant etre utilises comme cibles en vue du developpement de moyens de prevention et de controle d'infections bacteriennes et/ou de dissemination systemique
DK03762684T DK1523572T3 (da) 2002-07-09 2003-07-09 Patogenicitetsdeterminanter, der kan anvendes som mål for udviklingsmetoder til forebyggelse og bekæmpelse af bakterielle infektioner og/eller systemisk dissemination
DE60320797T DE60320797D1 (de) 2002-07-09 2003-07-09 Pathogene determinanten als zielmoleküle zur entwicklung von mitteln welche bakterielle infektionen und/oder systemische verbreitung verhindern und kontrollieren können
CA002491847A CA2491847A1 (fr) 2002-07-09 2003-07-09 Determinants de pathogenicite pouvant servir d'agents cibles dans l'elaboration de mesures de prevention et de reduction des infections bacteriennes ou de la dissemination systemique de microorganismes
JP2004518773A JP2006515155A (ja) 2002-07-09 2003-07-09 細菌感染および／または全身性播種の予防および制御手段開発に際し標的として使用し得る病原性決定基
HK05109367A HK1078902A1 (en) 2002-07-09 2005-10-20 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
US11/506,821 US20070111229A1 (en) 2002-07-09 2006-08-21 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
AU2009201727A AU2009201727A1 (en) 2002-07-09 2009-04-30 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
US12/729,630 US20110236886A1 (en) 2002-07-09 2010-03-23 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0208636A FR2842210B1 (fr) 2002-07-09 2002-07-09 Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique

Publications (2)

Publication Number Publication Date
FR2842210A1 FR2842210A1 (fr) 2004-01-16
FR2842210B1 true FR2842210B1 (fr) 2012-12-14

Family

ID=29763685

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0208636A Expired - Lifetime FR2842210B1 (fr) 2002-07-09 2002-07-09 Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique

Country Status (12)

Country Link
US (3) US20060003393A1 (fr)
EP (1) EP1523572B1 (fr)
JP (1) JP2006515155A (fr)
AT (1) ATE394503T1 (fr)
AU (2) AU2003266246A1 (fr)
CA (1) CA2491847A1 (fr)
DE (1) DE60320797D1 (fr)
DK (1) DK1523572T3 (fr)
ES (1) ES2306891T3 (fr)
FR (1) FR2842210B1 (fr)
HK (1) HK1078902A1 (fr)
WO (1) WO2004005535A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US20040247605A1 (en) * 2002-12-02 2004-12-09 Kokai-Kun John Fitzgerald Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
US20080002211A1 (en) * 2006-01-20 2008-01-03 The General Hospital Corporation System, arrangement and process for providing speckle reductions using a wave front modulation for optical coherence tomography
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
EP2464658B1 (fr) 2009-07-16 2014-10-01 Novartis AG Immunogène d'escherichia coli detoxifié
CA3021760A1 (fr) * 2016-04-25 2017-11-02 Aperture Bio, LLC Systemes, dispositifs et procedes d'analyse sequentielle d'echantillons matriciels complexes pour detection bacterienne de haute fiabilite et prediction de sensibilite aux medicam ents a l'aide d'un cytometre de flux
JP7515092B2 (ja) * 2017-10-18 2024-07-12 北海道公立大学法人 札幌医科大学 抗菌剤のスクリーニング方法
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN115725607B (zh) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) 一种鼻疽诺卡菌的致病靶基因及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020121A (en) * 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
WO1999066049A2 (fr) * 1998-06-12 1999-12-23 University Of Guelph Nouveau gene et procede de traitement d'une infection bacterienne gram negatif
CN1196787C (zh) * 1998-11-09 2005-04-13 微科学有限公司 毒力基因和蛋白质及其用途
EP1149166A2 (fr) * 1999-01-27 2001-10-31 Elitra Pharmaceuticals, Inc. Genes identifies intervenant dans la proliferation cellulaire d'escherichia coli
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique

Also Published As

Publication number Publication date
FR2842210A1 (fr) 2004-01-16
DK1523572T3 (da) 2008-09-08
AU2003266246A1 (en) 2004-01-23
US20070111229A1 (en) 2007-05-17
US20110236886A1 (en) 2011-09-29
DE60320797D1 (de) 2008-06-19
ATE394503T1 (de) 2008-05-15
US20060003393A1 (en) 2006-01-05
ES2306891T3 (es) 2008-11-16
JP2006515155A (ja) 2006-05-25
WO2004005535A3 (fr) 2004-11-18
HK1078902A1 (en) 2006-03-24
EP1523572A2 (fr) 2005-04-20
EP1523572B1 (fr) 2008-05-07
AU2009201727A1 (en) 2009-05-21
CA2491847A1 (fr) 2004-01-15
WO2004005535A2 (fr) 2004-01-15

Similar Documents

Publication Publication Date Title
de Breij et al. CsuA/BABCDE-dependent pili are not involved in the adherence of Acinetobacter baumannii ATCC19606T to human airway epithelial cells and their inflammatory response
Arciola et al. A multiplex PCR method for the detection of all five individual genes of ica locus in Staphylococcus epidermidis. A survey on 400 clinical isolates from prosthesis‐associated infections
Morona et al. The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae
Le Roux et al. Genome sequence of Vibrio splendidus: an abundant planctonic marine species with a large genotypic diversity
Connolly et al. The host metabolite D-serine contributes to bacterial niche specificity through gene selection
FR2842210B1 (fr) Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
Arciola et al. Search for the insertion element IS256 within the ica locus of Staphylococcus epidermidis clinical isolates collected from biomaterial-associated infections
Rogers et al. Adhesion by pathogenic corynebacteria
DE69841261D1 (de) Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
Minnick et al. Developmental biology of Coxiella burnetii
Safarchi et al. Better colonisation of newly emerged Bordetella pertussis in the co-infection mouse model study
Rumbaugh et al. Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection: variations in virulence factors and virulence genes
Gelosia et al. Phenotypic and genotypic markers of Staphylococcus epidermidis virulence
Calus et al. Protein variability among Mycoplasma hyopneumoniae isolates
Umeda et al. Adhesion and invasion to epithelial cells by fimA genotypes of Porphyromonas gingivalis
WO2002075507A3 (fr) Preparations de vaccin anti-bacteriennes
Davin-Regli et al. A nosocomial outbreak due to Enterobacter cloacae strains with the E. hormaechei genotype in patients treated with fluoroquinolones
WO2000061724A3 (fr) Compositions vaccinales anti-bacteriennes
Rico et al. Characterization of Vibrio harveyi strains recovered from diseased farmed Senegalese sole (Solea senegalensis)
AP1502A (en) Genes and proteins, and their uses.
Umeda et al. Differential transcription of virulence genes in Aggregatibacter actinomycetemcomitans serotypes
Jauregui et al. Differential interactions of S treptococcus gordonii and S taphylococcus aureus with cultured osteoblasts
Sakinç et al. The uropathogenic species Staphylococcus saprophyticus tolerates a high concentration of D-serine
Pan et al. A new gcrR‐deficient Streptococcus mutans mutant for replacement therapy of dental caries
Dinjus et al. Detection of the induction of Salmonella enterotoxin gene expression by contact with epithelial cells with RT-PCR

Legal Events

Date Code Title Description
TP Transmission of property
PLFP Fee payment

Year of fee payment: 14

TP Transmission of property

Owner name: MUTABILIS, FR

Effective date: 20160406

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16